Is Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Back In The Buying Zone?

Currently, there are 156.35M common shares owned by the public and among those 151.88M shares have been available to trade.

The company’s stock has a 5-day price change of -4.07% and -13.94% over the past three months. IRWD shares are trading -21.77% year to date (YTD), with the 12-month market performance down to -16.51% lower. It has a 12-month low price of $8.07 and touched a high of $15.70 over the same period. IRWD has an average intraday trading volume of 4.16 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -31.11%, -31.38%, and -16.90% respectively.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Institutional ownership of Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) shares accounts for 107.30% of the company’s 156.35M shares outstanding.

It has a market capitalization of $1.40B and a beta (3y monthly) value of 0.57. The earnings-per-share (ttm) stands at -$6.51. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.85% over the week and 5.24% over the month.

Analysts forecast that Ironwood Pharmaceuticals Inc (IRWD) will achieve an EPS of $0.16 for the current quarter, $0.18 for the next quarter and $0.86 for 2025. The lowest estimate earnings-per-share for the quarter is $0.1 while analysts give the company a high EPS estimate of $0.25. Comparatively, EPS for the current quarter was $0.25 a year ago. Earnings per share for the fiscal year are expected to increase by 110.85%, and 15.71% over the next financial year.

Looking at the support for the IRWD, a number of firms have released research notes about the stock. Craig Hallum stated their Buy rating for the stock in a research note on January 17, 2024, with the firm’s price target at $21. Wells Fargo coverage for the Ironwood Pharmaceuticals Inc (IRWD) stock in a research note released on December 14, 2023 offered a Overweight rating with a price target of $20. Jefferies was of a view on November 09, 2023 that the stock is Buy, while JMP Securities gave the stock Mkt Outperform rating on September 28, 2023, issuing a price target of $22. CapitalOne on their part issued Overweight rating on September 02, 2022.

Most Popular

Related Posts